Resource Center
Resource Center
CHAI has released the 13th issue of our annual HIV market report detailing the complex, ever-changing HIV commodity markets in low- and middle-income countries based on aggregated market intelligence from our work in over 20 countries.
Read moreA critical second-line HIV treatment called darunavir/ritonavir (DRV/r) is rolling out across Nigeria and Zambia – some of the earliest adopters of many countries that can now access an affordable supply of these medicines following a pricing agreement secured by CHAI and Unitaid last year.
Read moreCHAI releases the 12th issue of our annual HIV market report. This report provides a detailed look at the complex, ever-changing HIV commodity markets in low- and middle-income countries based on aggregated market intelligence from our work in over 30 countries.
Read moreThe report looks at the complex, ever-changing antiretroviral and diagnostic markets in low- and middle-income countries based on aggregated market intelligence from our programmatic work in over 30 countries.
Read moreOur monthly checkin with staff. Learn more about the people who work at CHAI.
Read moreThe 2017 Annual Report looks back at what we have accomplished over the year, as well as toward the goals that we have set for each of our programs over the next five to 10 years.
Read moreThis World AIDS Day, we celebrate the tremendous progress that has been made in response to the HIV/AIDS epidemic, with more than 20 million people living with HIV accessing life-saving antiretroviral treatment (ART) as of today. The incredible scale up of ART in developing countries, with affordable generic drugs widely available and the majority of...
Read moreThis webinar, the first in a two-part series, guides usage of CHAI’s HIV New Product Introduction Toolkit. The toolkit provides Ministries of Health and implementing partners with the tools necessary to evaluate the adoption and introduction of new HIV products in their local context. The webinar also provides an overview of the CHAI ARV Phase-In/Phase-Out...
Read moreThe HIV/AIDS community received good news ahead of the 2017 International AIDS Society (IAS) meeting in Paris: for the first time ever, more than 50 percent of people living with HIV were receiving antiretroviral therapy (ART) at the end of 2016 and AIDS-related deaths have halved since 2005. If this trend continues, the world will...
Read moreNegotiated pricing agreements have lowered costs and will improve access to quality treatment for people living with HIV New York – A breakthrough pricing agreement has been announced which will accelerate the availability of the first affordable, generic, single-pill HIV treatment regimen containing dolutegravir (DTG) to public sector purchasers in low- and middle-income countries...
Read more